我国近5年降脂药药物经济学研究文献分析
x

请在关注微信后,向客服人员索取文件

篇名: 我国近5年降脂药药物经济学研究文献分析
TITLE:
摘要: 目的:了解我国降脂药药物经济学研究的近况,寻求成本-效果较好的用药方案,为临床合理用药提供参考。方法:检索中国知网和万方数据知识服务平台,纳入2011-2015年国内发表的降脂药药物经济学文献并进行分析,探讨我国降脂药药物经济学研究中存在的问题,并提出相关建议。结果:瑞舒伐他汀等药的成本-效果较好,但目前国内发表的降脂药药物经济学研究文献尚存在研究方法不同、药物疗程长短不一、成本计算方法不同、效果指标单一和不良反应缺乏等问题,研究总体质量偏低,导致难以准确得出具有最佳成本-效果的药物。结论:今后的相关研究应该依据疾病种类与研究目的确定研究时限和健康产出指标、效果指标及评价方法,加强研究设计方法的统一性,并注意对成本进行贴现处理;此外,还应加强对中药降脂药的药物经济学研究,并与化学药进行比较。
ABSTRACT: OBJECTIVE: To investigate the situation of pharmacoeconomic researches about lipid-lowering drugs in China, and to seek the regimen with good cost-effectiveness in order to provide reference for rational drug use in the clinic. METHODS: Retrieved from CNKI and Wanfang database, pharmacoeconomic literatures about lipid-lowering drugs, published in domestic journals during 2011-2015, were included to discuss the problems of pharmacoeconomic researches about lipid-lowering drugs and put forward related suggestions. RESULTS: Rosuvastatin and other medicines showed good cost-effectiveness, while there were many problems of domestic published pharmacoeconomic researches about lipid-lowering drugs, such as different research methods, different treatment courses, different methods of cost calculation, single effect index and absence of ADR. On the whole, the researches were low in quality, which led the difficulty of accurately obtaining the drugs with best cost-effectiveness. CONCLUSIONS: In the future, related researches should confirm research duration and health output index, effect index and evaluation method according to disease types and research objectives; enhance the unity of research and design methods; pay attention to cost discount; in addition, strengthen pharmacoeconomic researches about lipid-lowering TCM and compare it with chemical drugs.
期刊: 2016年第27卷第26期
作者: 王艳春,吕巧莉,孙建勋,徐若南
AUTHORS: WANG Yanchun,LYU Qiaoli,SUN Jianxun,XU Ruonan
关键字: 降脂药;药物经济学;文献分析;问题;建议
KEYWORDS: Lipid-lowering drugs; Pharmacoeconomic; Literature analysis; Problems; Suggestions
阅读数: 409 次
本月下载数: 8 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!